Log in
Enquire now
‌

US Patent 10519229 Nucleic acids encoding IL-8 antibodies

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
Date Filed
May 10, 2018
Date of Patent
December 31, 2019
Patent Application Number
15976288
Patent Citations Received
‌
US Patent 11780912 Composition for prophylaxis or treatment of IL-8 related diseases
‌
US Patent 11359009 Anti-myostatin antibodies and methods of use
‌
US Patent 11359194 Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
0
‌
US Patent 11371039 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
‌
US Patent 10919953 FcgammaRIIB-specific Fc region variant
‌
US Patent 11046784 Methods for controlling blood pharmacokinetics of antibodies
‌
US Patent 11053308 Method for treating IL-8-related diseases
0
‌
US Patent 11248053 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
0
‌
US Patent 11267868 Fc region variant
‌
US Patent 11236168 Mouse FcγammaRII-specific Fc antibody
•••
Patent Inventor Names
Genki Nakamura
0
Atsuhiko Maeda
0
Kenta Haraya
0
Masaru Muraoka
0
Tatsuhiko Tachibana
0
Tomoyuki Igawa
0
Yuji Hori
0
Yuki Iwayanagi
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10519229
Patent Primary Examiner
‌
Prema M Mertz

Find more entities like US Patent 10519229 Nucleic acids encoding IL-8 antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.